- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK3) [2,4]. The discovery of LY2090314 is described by Engler et al. (2004)  where it is compound 12.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Doble BW, Woodgett JR. (2003)
GSK-3: tricks of the trade for a multi-tasking kinase.
J Cell Sci, 116 (Pt 7): 1175-86. [PMID:12615961]
2. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C et al.. (2004)
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
J Med Chem, 47 (16): 3934-7. [PMID:15267232]
3. Jope RS, Yuskaitis CJ, Beurel E. (2007)
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.
Neurochem Res, 32 (4-5): 577-95. [PMID:16944320]
4. Vadivelan S, Sinha BN, Tajne S, Jagarlapudi SA. (2009)
Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Eur J Med Chem, 44 (6): 2361-71. [PMID:18929433]